ClinicalTrials.Veeva

Menu

MAP THE SMA: a Machine-learning Based Algorithm to Predict THErapeutic Response in Spinal Muscular Atrophy (MAP_THE_SMA-01)

I

Institute of Hospitalization and Scientific Care (IRCCS)

Status

Enrolling

Conditions

Spinal Muscular Atrophy

Treatments

Drug: disease modifying treatments

Study type

Observational

Funder types

Other

Identifiers

NCT05769465
5488
GR-2021-12374579 (Other Grant/Funding Number)

Details and patient eligibility

About

Spinal Muscular Atrophy (SMA) is caused by the homozygous loss of the Survival Motor Neuron (SMN) 1 gene, which leads to degeneration of spinal alpha-motor neurons and muscle atrophy. Three treatments have been approved for SMA but the available data show interpatient variability in therapy response and, to date, individual factors such as age or SMN2 copies,cannot fully explain this variance.

The aim of this project is:

  • collect clinical data and patient-reported outcome measures (PROM) from patients treated with nusinersen, risdiplam, onasemnogene abeparvovec,
  • identify novel biomarkers and RNA molecular signature profiling,
  • develop a predictive algorithm using artificial intelligence (AI) methodologies based on machine learning (ML), able to integrate clinical outcomes, patients' characteristics, and specific biomarkers.

This effort will help to better stratify the SMA patients and to predict their therapeutic outcome, thus to address patients towards personalized therapies.

Enrollment

247 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • confirmed genetic diagnosis of SMA (5q)
  • clinical phenotype of type I or II or III;
  • able to provide (patient/caregiver) written informed consent

Exclusion criteria

  • None

Trial design

247 participants in 4 patient groups

Patients treated with nusinersen
Treatment:
Drug: disease modifying treatments
Patients treated with risdiplam
Treatment:
Drug: disease modifying treatments
Patients treated with onasemnogene abeparvovec
Treatment:
Drug: disease modifying treatments
Patients naive from disease modifying treatments

Trial contacts and locations

1

Loading...

Central trial contact

Comitato Etico

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems